Cargando…
Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
OBJECTIVE: To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on serum immunoglobulin (Ig) concentrations and B lymphocyte counts in patients with ANCA-associated vasculitides (AAVs). METHODS: Retrospective analysis of Ig concentrations and peripheral B...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357389/ https://www.ncbi.nlm.nih.gov/pubmed/22629432 http://dx.doi.org/10.1371/journal.pone.0037626 |
_version_ | 1782233665501134848 |
---|---|
author | Venhoff, Nils Effelsberg, Nora M. Salzer, Ulrich Warnatz, Klaus Peter, Hans Hartmut Lebrecht, Dirk Schlesier, Michael Voll, Reinhard E. Thiel, Jens |
author_facet | Venhoff, Nils Effelsberg, Nora M. Salzer, Ulrich Warnatz, Klaus Peter, Hans Hartmut Lebrecht, Dirk Schlesier, Michael Voll, Reinhard E. Thiel, Jens |
author_sort | Venhoff, Nils |
collection | PubMed |
description | OBJECTIVE: To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on serum immunoglobulin (Ig) concentrations and B lymphocyte counts in patients with ANCA-associated vasculitides (AAVs). METHODS: Retrospective analysis of Ig concentrations and peripheral B cell counts in 55 AAV patients. RESULTS: CYC treatment resulted in a decrease in Ig levels (median; interquartile range IQR) from IgG 12.8 g/L (8.15-15.45) to 9.17 g/L (8.04-9.90) (p = 0.002), IgM 1.05 g/L (0.70-1.41) to 0.83 g/L (0.60-1.17) (p = 0.046) and IgA 2.58 g/L (1.71-3.48) to 1.58 g/L (1-31-2.39) (p = 0.056) at a median follow-up time of 4 months. IgG remained significantly below the initial value at 14.5 months and 30 months analyses. Subsequent RTX treatment in patients that had previously received CYC resulted in a further decline in Ig levels from pre RTX IgG 9.84 g/L (8.71-11.60) to 7.11 g/L (5.75-8.77; p = 0.007), from pre RTX IgM 0.84 g/L (0.63-1.18) to 0.35 g/L (0.23-0.48; p<0.001) and from pre RTX IgA 2.03 g/L (1.37-2.50) to IgA 1.62 g/L (IQR 0.84-2.43; p = 0.365) 14 months after RTX. Treatment with RTX induced a complete depletion of B cells in all patients. After a median observation time of 20 months median B lymphocyte counts remained severely suppressed (4 B-cells/µl, 1.25-9.5, p<0.001). Seven patients (21%) that had been treated with CYC followed by RTX were started on Ig replacement because of severe bronchopulmonary infections and serum IgG concentrations below 5 g/L. CONCLUSIONS: In patients with AAVs, treatment with CYC leads to a decline in immunoglobulin concentrations. A subsequent RTX therapy aggravates the decline in serum immunoglobulin concentrations and results in a profoundly delayed B cell repopulation. Surveying patients with AAVs post CYC and RTX treatment for serum immunoglobulin concentrations and persisting hypogammaglobulinemia is warranted. |
format | Online Article Text |
id | pubmed-3357389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33573892012-05-24 Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides Venhoff, Nils Effelsberg, Nora M. Salzer, Ulrich Warnatz, Klaus Peter, Hans Hartmut Lebrecht, Dirk Schlesier, Michael Voll, Reinhard E. Thiel, Jens PLoS One Research Article OBJECTIVE: To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on serum immunoglobulin (Ig) concentrations and B lymphocyte counts in patients with ANCA-associated vasculitides (AAVs). METHODS: Retrospective analysis of Ig concentrations and peripheral B cell counts in 55 AAV patients. RESULTS: CYC treatment resulted in a decrease in Ig levels (median; interquartile range IQR) from IgG 12.8 g/L (8.15-15.45) to 9.17 g/L (8.04-9.90) (p = 0.002), IgM 1.05 g/L (0.70-1.41) to 0.83 g/L (0.60-1.17) (p = 0.046) and IgA 2.58 g/L (1.71-3.48) to 1.58 g/L (1-31-2.39) (p = 0.056) at a median follow-up time of 4 months. IgG remained significantly below the initial value at 14.5 months and 30 months analyses. Subsequent RTX treatment in patients that had previously received CYC resulted in a further decline in Ig levels from pre RTX IgG 9.84 g/L (8.71-11.60) to 7.11 g/L (5.75-8.77; p = 0.007), from pre RTX IgM 0.84 g/L (0.63-1.18) to 0.35 g/L (0.23-0.48; p<0.001) and from pre RTX IgA 2.03 g/L (1.37-2.50) to IgA 1.62 g/L (IQR 0.84-2.43; p = 0.365) 14 months after RTX. Treatment with RTX induced a complete depletion of B cells in all patients. After a median observation time of 20 months median B lymphocyte counts remained severely suppressed (4 B-cells/µl, 1.25-9.5, p<0.001). Seven patients (21%) that had been treated with CYC followed by RTX were started on Ig replacement because of severe bronchopulmonary infections and serum IgG concentrations below 5 g/L. CONCLUSIONS: In patients with AAVs, treatment with CYC leads to a decline in immunoglobulin concentrations. A subsequent RTX therapy aggravates the decline in serum immunoglobulin concentrations and results in a profoundly delayed B cell repopulation. Surveying patients with AAVs post CYC and RTX treatment for serum immunoglobulin concentrations and persisting hypogammaglobulinemia is warranted. Public Library of Science 2012-05-21 /pmc/articles/PMC3357389/ /pubmed/22629432 http://dx.doi.org/10.1371/journal.pone.0037626 Text en Venhoff et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Venhoff, Nils Effelsberg, Nora M. Salzer, Ulrich Warnatz, Klaus Peter, Hans Hartmut Lebrecht, Dirk Schlesier, Michael Voll, Reinhard E. Thiel, Jens Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides |
title | Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides |
title_full | Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides |
title_fullStr | Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides |
title_full_unstemmed | Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides |
title_short | Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides |
title_sort | impact of rituximab on immunoglobulin concentrations and b cell numbers after cyclophosphamide treatment in patients with anca-associated vasculitides |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357389/ https://www.ncbi.nlm.nih.gov/pubmed/22629432 http://dx.doi.org/10.1371/journal.pone.0037626 |
work_keys_str_mv | AT venhoffnils impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides AT effelsbergnoram impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides AT salzerulrich impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides AT warnatzklaus impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides AT peterhanshartmut impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides AT lebrechtdirk impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides AT schlesiermichael impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides AT vollreinharde impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides AT thieljens impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides |